The biggest PBMs are handling more and more of the country’s drug price negotiations
The PBM industry has only grown despite its motto of lowering drug costs, and concerns remain about PBMs' incentives and contract terms.
Read The StoryBusiness
Exploring the intersection of finance, pharma, and biotech
‘It’s not medical’: Oregon wrestles with how to offer psychedelics outside the health care system
How America’s largest Catholic hospital system is moonlighting as a private equity firm
A ‘Shark Tank’-funded test for food sensitivity is medically dubious, experts say
Anxious about a big speech? This startup wants to calm you down — with a cardiac drug you pop like a mint
All Coverage
advertisement
